Hoechst: VRS write-off depresses earnings - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Hoechst: VRS write-off depresses earnings

May 29, 2000

While Hoechst Marion Roussel (HMR) announced a 35% rise in the net profit and this seemed to be on the back of the increased other income which accrued from the sale of its property in Mulund as well the sale of its tail end brands Omnatax and Haemaccel, the company has provided for a huge charge on account of Voluntary Retirement Scheme (included in its total expenditure) amounting to Rs 220 m during the year. This signifies that the rise in profits has accrued from operations themselves and is very impressive keeping in mind the fact that almost 60% of the company’s revenues accrue from products under price control.

A relaxation in the Drug Price Control Order if it were to come about, could lead to an explosive growth in the bottomline. For instance Daonil, the company’s anti–diabetes drug sells at 25 paise per tablet. HMR sells almost a billion tablets annually and even a 15 paise increase in the price would swell HMR’s bottomline by Rs 150 m (i.e. almost 50% from current levels).

Even if the relaxation in the DPCO does not materialise, the increase in profits would be the led by the relatively higher profits from new products such as Cardace (cardiovascular) Amaryl (an oral anti–diabetic), Cefrom (antibiotic) and Frisium (anti–epileptic), which are outside the purview of the DPCO.

The fact that the company does not have a 100% subsidiary and has no plans to do so in the immediate future implies that the company will continue to have access to its parent Aventis’ product pipeline.

Equitymaster requests your view! Post a comment on "Hoechst: VRS write-off depresses earnings". Click here!

  

More Views on News

SANOFI INDIA Announces Quarterly Results (2QFY21); Net Profit Up 5.0% (Quarterly Result Update)

Oct 29, 2020 | Updated on Oct 29, 2020

For the quarter ended September 2020, SANOFI INDIA has posted a net profit of Rs 1 bn (up 5.0% YoY). Sales on the other hand came in at Rs 7 bn (down 11.9% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

SANOFI INDIA Announces Quarterly Results (1QFY21); Net Profit Up 39.9% (Quarterly Result Update)

Aug 26, 2020 | Updated on Aug 26, 2020

For the quarter ended June 2020, SANOFI INDIA has posted a net profit of Rs 1 bn (up 39.9% YoY). Sales on the other hand came in at Rs 7 bn (down 5.0% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games? (The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

4 Stocks to Make Your Portfolio Immune to the Second Covid Wave (Profit Hunter)

Apr 6, 2021

Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.

An India Revival Stock I'm Bullish On... (Profit Hunter)

Apr 9, 2021

This could take India to the position of 3rd largest economy.

Why Did the Market Crash on Monday? (Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

A Unique Sector for Short-Term Profits (Fast Profits Daily)

Apr 12, 2021

This ignored sector could deliver big short-term profits.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

SANOFI INDIA SHARE PRICE


Apr 16, 2021 (Close)

TRACK SANOFI INDIA

  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SANOFI INDIA - AJANTA PHARMA COMPARISON

COMPARE SANOFI INDIA WITH

MARKET STATS